QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

The five pillars – Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON for latent tuberculosis testing – represent areas where QIAGEN has established leadership and scaling differentiated platforms with growth potential. VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, r ...